Amgen disclosed its Q2 capital expenditures were $500 million, primarily for U.S. manufacturing sites. The company reiterated its expectation of approximately $2.6 billion in capital expenditures for 2026 to scale manufacturing capacity, including for the launch of Maritide, and anticipates a meaningful sequential increase in Q3 operating expenses.
Amgen's disclosure of $500 million in Q2 capital expenditures and the reaffirmation of $2.6 billion in capex for 2026 signals significant investment in manufacturing infrastructure, particularly for new product launches like Maritide. This indicates a long-term growth strategy and commitment to scaling production, which is generally positive for future revenue streams. However, the anticipated 'meaningful sequential increase in operating expenses in Q3' could put short-term pressure on profitability, potentially leading to some investor caution. For traders, the long-term investment in manufacturing capacity presents an opportunity for sustained growth, while the short-term increase in operating expenses might create a temporary headwind.